Advances in neoadjuvant therapy for locally advanced resectable esophageal cancer
- VernacularTitle:局部进展期可切除食管癌的新辅助治疗进展
- Author:
Xiaozheng KANG
1
;
Ruixiang ZHANG
1
;
Zhen WANG
1
;
Xiankai CHEN
1
;
Yong LI
1
;
Jianjun QIN
1
;
Yin LI
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
neoadjuvant therapy;
esophagectomy;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(02):153-159
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy has become the standard treatment for locally advanced resectable esophageal cancer, significantly improving long-term survival compared to surgery alone. Neoadjuvant therapy has evolved to include various strategies, such as concurrent chemoradiotherapy, chemotherapy, immunotherapy, or targeted combination therapy. This enriches clinical treatment options and provides a more personalized and scientific treatment approach for patients. This article aims to comprehensively summarize current academic research hot topics, review the rationale and evaluation measures of neoadjuvant therapy, discuss challenges in restaging methods after neoadjuvant therapy, and identify the advantages and disadvantages of various neoadjuvant therapeutic strategies.
